Pathology, Inc.

DUBLIN, March 28, 2024 /PRNewswire/ -- The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering. The Clinical Laboratory rose to the COVID challenge, but the end of the pandemic has created a new approach to diagnostics. Point of Care and Self Testing are threatening long term demand for clinical lab services but Molecular Diagnostics is driving runaway growth. Understand the opportunities and the threats in this comprehensive report. The fundamentals are still here. Clinical laboratory testing is positioned to directly benefit from the explosion in biotechnology, especially genomics. A range of dynamic trends are pushing market growth and company valuations. Trends like: The genetic blizzard Emerging economies and global prosperity Pharmacogenomics Healthcare expansion in China Climate change Globalization Automation Exciting technical developments especially in the area of molecular diagnostics and pharmacogenomics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. The report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current United States Medicare Fee Payment Schedules to help sharpen your pricing. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Based on extensive primary and secondary research the testing volume data is broken down into price and volumes allowing researchers and investors to quickly create informed and reasonable forecasts of demand. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. The report includes detailed breakouts for 15 Countries and 4 Regions. The report includes five year market forecasts. Key Topics Covered: 1 Market Guides 1.1 Clinical Laboratory Services - Strategic Situation Analysis and Covid-19 Impact 1.2 Guide for Executives, Marketing, Sales and Business Development Staff 1.3 Guide for Management Consultants and Investment Advisors 2 Introduction and Market Definition 2.1 The Growing Demand for Clinical Testing 2.2 Defining the Opportunity 2.2.1 Volumes 2.2.2 Prices 2.2.3 Revenue Market Size 2.3 Methods and Sources 2.3.1 Authors 2.3.2 Sources 2.4 Perspective: Healthcare, the IVD Industry, and the COVID-19 Pandemic 2.4.1 Global Healthcare Spending 2.4.2 Spending on Diagnostics 2.4.3 Important Role of Insurance for Diagnostics 3 Overview of a Dynamic Market 3.1 Players in a Dynamic Market 3.1.1 Academic Research Lab 3.1.2 Diagnostic Test Developer 3.1.3 Genomic Instrumentation Supplier 3.1.4 Pharmaceutical/Reagent Supplier 3.1.5 Independent Testing Lab 3.1.6 Public National/regional lab 3.1.7 Hospital lab 3.1.8 Physician Lab 3.1.9 Audit Body 3.1.10 Certification Body 3.2 Segmentation - Different Approaches 3.2.1 Traditional Market Segmentation 3.2.2 Laboratory Focus and Segmentation 3.3 Structure of Clinical Testing Industry 3.3.1 The Hospital Lab - Share of the Pie 3.3.2 Key Role for Economies of Scale 3.3.3 Physician Office Lab's are Still Here 3.3.4 Physician's and POCT - Reviving Patient Service in China 3.4 National and Regional Diversity 4 Trends Driving a Changing Market 4.1 Growth Is Pushed from Many Sides 4.1.1 Understanding the Impact of Aging Population 4.1.2 COVID Related Testing Growth 4.1.3 Point of Care Testing can increase demand 4.1.4 Alternative Medicine Creates Testing Opportunity 4.1.5 Esoteric Testing Moving Mainstream 4.1.6 Genetic Based Testing Creates New Department and New Discipline 4.2 Factors at Work to Shrink the Market 4.2.1 Lower Unit Costs 4.2.2 Economic or population contraction 4.2.3 Testing usage analysis curtailing growth 4.2.4 Wellness has a downside 4.2.5 Test Displacement Impacts Important 4.2.6 Point of Care Testing 4.3 Automation 4.3.1 Stranded LIMS Investment 4.3.2 Software as a Service 4.3.3 Physician Office and Access Systems 4.4 Environment and Evolution 4.5 Diagnostic Technology Development 4.5.1 Next Generation Sequencing Fuels a Revolution 4.5.2 Impact of NGS on pricing 4.5.3 POCT/Self Testing Disruptive Force 4.5.4 Pharmacogenomics Blurs Diagnosis and Treatment 4.5.5 CGES Testing, A Brave New World 4.5.6 Molecular Diagnostics Technologies at The Forefront of Growth 4.5.7 Biochips/Giant magneto resistance based assay 5 Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 5.1 Recent Developments - Importance and How to Use This Section 5.1.1 Importance of These Developments 5.1.2 How to Use This Section 5.2 Seegene to Enter Syndromic MDx Space 5.3 EKF Diagnostics Acquires Advanced Diagnostic Laboratory 5.4 Molecular Health, EDGC Ink Liquid Biopsy Partnership 5.5 ProPhase Labs Acquires Nebula Genomics for $14.6M 5.6 Karius Cell-Free DNA Method to Detect Infection Validated 5.7 South Korean Firm EDGC to Expand Into Liquid Biopsy Space With Cf DNA Platform 5.8 TruDiagnostic Receives CLIA Certification for Kentucky Laboratory 5.9 Enzo Biochem Q2 Revenues Up 62 Percent 5.10 Thermo Fisher Gets CE Mark for High-Throughput COVID-19 Assay 5.11 FDA Issues Alert - False Negatives due to SARS-CoV-2 Mutations 5.12 Will Labs Use Expanded Molecular Testing Capacities Post-COVID-19? 5.13 Chinese Infectious Dx Firm Vision Medicals Completes Series B Financing 5.14 Cooperative Aims to Expand Clinical, Commercial NGS Access 5.15 Emerging COVID-19 Sequencing Assays - An Alternative to Existing Diagnostics? 5.16 CDC Ranks Two More Microbes as 'Urgent Threat' 5.17 ACLA Requests $5 billion to keep private labs going 5.18 Applied Biology to Launch New Laboratory for Hair and Skin Disorders 5.19 Quest Diagnostics Acquires Outreach Operations 5.20 Quest Diagnostics Buys Assets of Boston Clinical Laboratory Services 5.21 CLA Urges FDA to Halt Crackdown on PGx Testing 5.22 Quest Diagnostics Subsidiary Buys True Health Dx Assets 5.23 BioReference Laboratories selected by IPA Association 6 Profiles of Key Companies Acibadem Labmed Laboratory ACM Medical Laboratory Adicon Clinical Laboratories American Bio-Clinical Laboratories, Int'l American Pathology Partners ARUP Laboratories Ascend Clinical Assurance Scientific Laboratories Aurora Diagnostics Bio-Reference Laboratories Bioscientia Institut fur Medizinische Diagnostik GmbH BP Healthcare Group Clinical Reference Laboratory Clongen Laboratories CompuNet Clinical Laboratories Diagnosticos da America DIAN Diagnostics Co., Ltd. Enzo Biochem Eone Laboratories Eurofins Scientific Exagen Diagnostics Genzyme Corporation Gribbles Pathology Guangzhou Kingmed Diagnostics Group Co., Ltd. Integrated Regional Laboratories KDL Group Laboratory Corporation of America Lifelabs Mayo Clinic Laboratories Mid America Clinical Laboratories MNG Labs Myriad Genetics/Myriad RBM NeoGenomics OncoDNA Pathology, Inc. ProPhase Labs Psychemedics Corporation Quest Diagnostics RDL Reference Laboratory Sonic Healthcare Spectra Laboratories Sysmex Inostics Unilabs For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

After 10 years in business, company rebrands to expand service offering. HEMET, Calif. , Feb. 26, 2024 /PRNewswire/ -- Mountain View Medical Laboratory, a leading and established lab backed by a decade of experience in providing a comprehensive range of testing solutions, today announced a complete rebranding to become "Gnosis." For 10 years, Mountain View Medical Laboratory (MVML) has been a trusted provider of clinical lab services in Riverside County, California. The laboratory offers providers, patients, and partners a range of services including routine blood work, pharmacogenomics, infectious disease testing, and toxicology utilizing high complexity urine drug testing. Gnosis is proud to offer the same great care Mountain View Medical Laboratory always has, now with expanded services and more innovative expertise. The organization will cater to a larger population, by uniting two state-of-the-art laboratories in Hemet and Orange, California. Gnosis has also expanded their network of in-network payor contracts, encompassing most major insurance payors and providers, including participation with Medicare/Medicaid. "This in-network initiative solidifies our commitment to providing accessible testing solutions to our partners and patients alike," said Matt Collins, CEO at Gnosis. "Our commitment to better patient care goes beyond financial consideration, it is about fostering collaboration and broadening our reach to support a wider spectrum of patients." Enhanced services from Gnosis include: State-of-the-art technology platforms for accurate and rapid turnarounds Interoperability with provider Electronic Medical Record (EMR) systems Fast integrations with most popular provider EMRs A full-featured provider portal Dedicated client success team standing by for all customer service needs Daily specimen pickup and courier services Gnosis is the product of seasoned leaders and top professionals in laboratory, public health, and community care services. Executive team members include: Matt Collins, President - a seasoned entrepreneur recognized for his expertise in business innovation and strategic scaling. Before assuming leadership at Gnosis, Matt successfully directed the operations of a COVID-19 testing service provider and laboratory that served over eight million patients. He oversaw a nationwide network of COVID-19 testing and vaccination sites, where he orchestrated comprehensive healthcare solutions. Safedin "Sajo" Beqaj, Ph.D., HCLD, CC(ABB), Medical Laboratory Director - Dr. Sajo Beqaj is board certified in molecular pathology and genetics and licensed as a Bioanalyst and High Complexity Laboratory Director. He has been practicing as a laboratory director since 2005. Doctor Beqaj, served as a technical director and was part of the initial management team for several well-known laboratories in the clinical lab industry including PathGroup, Nashville, TN; DCL Medical Laboratories, Indianapolis, IN, Pathology, Inc, Torrance, CA, and Mountain View Medical Laboratory, Hemet, CA. For more information on Gnosis, please visit . About Gnosis, Powered by Mountain View Medical Laboratory Gnosis is a full service, state-of-the-art diagnostic laboratory with locations in Hemet, Orange, and Palo Alto, California. For over 10 years, their laboratories have offered providers and patients a comprehensive range of services, including routine blood work, pharmacogenomics, infectious disease testing, and toxicology utilizing high complexity urine drug testing. To learn more, please visit Media Contact Hall Roosevelt [email protected] 949.443.9300 SOURCE Gnosis

DUBLIN, Oct. 7, 2022 /PRNewswire/ -- The "Digital Pathology Market by Product( ArtificiaI Intelligence, Scanner, Software, Storage), Type(Human, Veterinary), Application( Teleconsultation, Training, Disease Diagnosis, Drug Discovery), End User( Pharma, Academia, Hospitals ) - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering. The global digital pathology market is projected to reach USD 1,371 million by 2026 from USD 736 million in 2021, at a CAGR of 13.2% during the forecast period. The growth in the digital pathology market is mainly driven by factors such as the increasing adoption of digital pathology to enhance lab efficiency, rising incidence of cancer, and growing applications of digital pathology in drug development and companion diagnostics. On the other hand, the high costs of digital pathology systems are expected to restrain market growth to a certain extent. The scanners segment accounted for the largest share of the Digital Pathology market in 2020. Based n products, the digital pathology market has been segmented into scanners, software, and storage systems. The large share of the scanners segment can be attributed to the high price of scanners and the increasing adoption of digital pathology solutions. The human pathology segment accounted for the largest share of the Digital Pathology market in 2020 Based on type, the global digital pathology market is segmented into human pathology and veterinary pathology. The human pathology segment accounted for the largest share of the digital pathology market in 2020. This is due to the increasing number of cancer research activities and growing collaborations among research institutes, universities, and pathology laboratories. The drug discovery, segment accounted for the largest share of the Digital Pathology market in 2020. Based on application, the digital pathology market is segmented into drug discovery, disease diagnosis, and training & education. The drug discovery segment accounted for the largest share of the digital pathology market in 2020. Growth in R&D expenditure fueled by the need for numerous preclinical and clinical studies performed during the drug discovery and development process is a major factor responsible for market growth. The pharmaceutical & biotechnology companies, segment accounted for the largest share of the Digital Pathology market in 2020. Based on end users, the global digital pathology market is segmented into pharmaceutical & biotechnology companies, hospitals & reference laboratories, and academic & research institutes. The pharmaceutical & biotechnology companies segment accounted for the largest share of the digital pathology market in 2020. The large share of this segment can be attributed to the increasing use of digital pathology for drug discovery studies and drug toxicology testing. Biotechnology companies also use digital pathology for biobanking, biopharmaceutical studies, molecular assays, and the development of individualized medicine. The market in North America is projected to witness the highest growth rate during the forecast period (2021-2026). North America accounted for the largest share of the digital pathology market in 2020. The increasing prevalence of cancer, rising demand for quality diagnostics, the introduction of favorable reimbursement policies, and the implementation of favorable initiatives by the governments in the US and Canada are major factors driving the growth of the digital pathology market in North America. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 4.1 Digital Pathology Market Overview 4.2 North America: Digital Pathology Market, by End-User & Country (2020) 4.3 Digital Pathology Market: Geographic Growth Opportunities 4.4 Regional Mix: Digital Pathology Market (2021-2026) 4.5 Digital Pathology Market: Developing Vs. Developed Markets 5 Market Overview 5.1 Introduction 5.2 Market Dynamics 5.2.1 Drivers 5.2.1.1 Increasing Adoption of Digital Pathology to Enhance Lab Efficiency 5.2.1.2 Rising Incidence of Cancer 5.2.1.3 Growing Applications of Digital Pathology in Drug Development and Companion Diagnostics 5.2.2 Restraints 5.2.2.1 High Cost of Digital Pathology Systems 5.2.3 Opportunities 5.2.3.1 Introduction of Affordable Scanners for Private Pathology Practices 5.2.3.2 Growing Demand for Personalized Medicine 5.2.3.3 High Growth Opportunities in Emerging Economies 5.2.4 Challenges 5.2.4.1 Shortage of Trained Pathologists 5.3 COVID-19 Impact Analysis 5.3.1 Impact of COVID-19 on the Digital Pathology Market 5.4 Ecosystem Market Map 5.5 Trends in Average Selling Price 5.6 Impact of the New Ivd Regulation on Different Markets 5.6.1 Impact on Clinical Lab Services 5.6.2 Impact on Ivd 5.6.3 Impact on Digital Pathology 5.7 Technology Analysis 5.7.1 Artificial Intelligence (Ai) in Digital Pathology 5.8 Patent Analysis 5.8.1 Methodology 5.8.2 Publication Trends 5.8.3 Jurisdiction Analysis 5.8.4 Top Applicants 6 Digital Pathology Market, by Product 6.1 Introduction 6.2 Scanners 6.2.1 Scanners Accounted for the Largest Share of the Digital Pathology Products Market in 2020 6.2.1.1 Brightfield Scanners 6.2.1.2 Other Scanners 6.3 Software 6.3.1 Integrated Software 6.3.1.1 Integrated Software Segment to Dominate the Market During the Forecast Period 6.3.2 Standalone Software 6.3.2.1 Information Management Software 6.3.2.1.1 Information Management Software Enables Comprehensive Integration with Any Institute's Information Systems 6.3.2.2 Image Analysis Software 6.3.2.2.1 Image Analysis Software Provides Easy-To-Use Solutions for the Quantitative Evaluation of Brightfield Slides 6.4 Storage Systems 6.4.1 Requirement for the Safe and Reliable Storage of High-Quality Images to Ensure Market Growth 7 Digital Pathology Market, by Type 7.1 Introduction 7.2 Human Pathology 7.2.1 the COVID-19 Pandemic Has Led to An Increasing Demand for Digital Pathology Solutions 7.3 Veterinary Pathology 7.3.1 Veterinary Digital Pathology Reduces the Turnaround Time for Animal Disease Diagnosis?Key Factor Driving the Market Growth 8 Digital Pathology Market, by Application 8.1 Introduction 8.2 Drug Discovery 8.2.1 Increasing R&D Spending to Drive the Growth of this Segment 8.3 Disease Diagnosis 8.3.1 Use of Artificial Intelligence and Machine Learning in Digital Pathology Solutions for Diagnostic Purposes to Drive Market Growth 8.4 Training & Education 8.4.1 Digital Pathology Can Improve Education & Training Provided to Pathologists in Academic Institutes 9 Digital Pathology Market, by End-User 9.1 Introduction 9.2 Pharmaceutical & Biotechnology Companies 9.2.1 Pharmaceutical & Biotechnology Companies Are the Largest & Fastest-Growing End-Users of the Digital Pathology Market 9.3 Hospitals & Reference Laboratories 9.3.1 Increasing Adoption of Digital Pathology Solutions in Hospitals to Drive the Growth of this Segment 9.4 Academic & Research Institutes 9.4.1 Funding Investments and Initiatives to Boost the Growth of this End-User Segment in the Digital Pathology Market 10 Digital Pathology Market, by Region 11 Competitive Landscape 11.1 Overview 11.2 Key Player Strategies/Right-To-Win 11.3 Revenue Share Analysis of Top Market Players 11.4 Competitive Benchmarking 11.5 Competitive Leadership Mapping 11.5.1 Stars 11.5.2 Emerging Leaders 11.5.3 Pervasive Players 11.5.4 Participants 11.6 Competitive Leadership Mapping for Other Companies 11.6.1 Progressive Companies 11.6.2 Dynamic Companies 11.6.3 Starting Blocks 11.6.4 Responsive Companies 11.7 Market Share Analysis 11.8 Competitive Scenario 11.8.1 Product Launches and Approvals 11.8.2 Deals 12 Company Profiles 12.1 Key Players 12.1.1 Leica Biosystems 12.1.1.1 Business Overview 12.1.1.2 Products & Services Offered 12.1.1.3 Recent Developments 12.1.1.4 Analyst's View 12.1.1.4.1 Right-To-Win 12.1.1.4.2 Strategic Choices Made 12.1.1.4.3 Weaknesses and Competitive Threats 12.1.2 Koninklijke Philips N.V. 12.1.2.1 Business Overview 12.1.2.2 Products & Services Offered 12.1.2.3 Recent Developments 12.1.2.4 Analyst's View 12.1.2.4.1 Right-To-Win 12.1.2.4.2 Strategic Choices Made 12.1.2.4.3 Weaknesses and Competitive Threats 12.1.3 Hamamatsu Photonics 12.1.3.1 Business Overview 12.1.3.2 Products & Services Offered 12.1.3.3 Recent Developments 12.1.3.4 Analyst's View 12.1.3.4.1 Right-To-Win 12.1.3.4.2 Strategic Choices Made 12.1.4 F. Hoffmann-La Roche Ltd. 12.1.4.1 Business Overview 12.1.4.2 Products Offered 12.1.4.3 Recent Developments 12.1.4.4 Analyst's View 12.1.4.4.1 Right-To-Win 12.1.4.4.2 Strategic Choices Made 12.1.5 Sectra Ab 12.1.5.1 Business Overview 12.1.5.2 Products Offered 12.1.5.3 Recent Developments 12.1.5.4 Analyst's View 12.1.5.4.1 Right-To-Win 12.1.5.4.2 Strategic Choices Made 12.1.6 Akoya Biosciences 12.1.6.1 Business Overview 12.1.6.2 Products Offered 12.1.6.3 Recent Developments 12.1.7 3Dhistech 12.1.7.1 Business Overview 12.1.7.2 Products Offered 12.1.7.3 Recent Developments 12.1.8 Apollo Enterprise Imaging Corp. 12.1.8.1 Business Overview 12.1.8.2 Products Offered 12.1.8.3 Recent Developments 12.1.9 Xifin, Inc. 12.1.9.1 Business Overview 12.1.9.2 Products Offered 12.1.9.3 Recent Developments 12.1.10 Huron Digital Pathology 12.1.10.1 Business Overview 12.1.10.2 Products Offered 12.1.10.3 Recent Developments 12.1.11 Visiopharm 12.1.11.1 Business Overview 12.1.11.2 Products Offered 12.1.11.3 Recent Developments 12.1.12 Corista 12.1.12.1 Business Overview 12.1.12.2 Products Offered 12.1.12.3 Recent Developments 12.1.13 Indica Labs 12.1.13.1 Business Overview 12.1.13.2 Products Offered 12.1.13.3 Recent Developments 12.1.14 Objective Pathology Services 12.1.14.1 Business Overview 12.1.14.2 Products Offered 12.1.15 Optrascan, Inc. 12.1.15.1 Business Overview 12.1.15.2 Products Offered 12.1.15.3 Recent Developments 12.1.16 Glencoe Software, Inc. 12.1.16.1 Business Overview 12.1.16.2 Products Offered 12.1.17 Aiforia Technologies Oy 12.1.17.1 Business Overview 12.1.17.2 Products Offered 12.1.17.3 Recent Developments 12.1.18 Paige 12.1.18.1 Business Overview 12.1.18.2 Products Offered 12.1.18.3 Recent Developments 12.1.19 Inspirata, Inc. 12.1.19.1 Business Overview 12.1.19.2 Products Offered 12.1.19.3 Recent Developments 12.1.20 Proscia, Inc. 12.1.20.1 Business Overview 12.1.20.2 Products Offered 12.1.20.3 Recent Developments 12.2 Other Players 12.2.1 Pathai 12.2.2 Konfoong Biotech International Co. Ltd. 12.2.3 Mikroscan Technologies, Inc. 12.2.4 Motic Digital Pathology 12.2.5 Kanteron Systems 13 Appendix For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets